Copper-ATSM as a Treatment for ALS: Support from Mutant SOD1 Models and Beyond
The blood–brain barrier permeant, copper-containing compound, Cu<sup>II</sup>(atsm), has successfully progressed from fundamental research outcomes in the laboratory through to phase 2/3 clinical assessment in patients with the highly aggressive and fatal neurodegenerative condition of a...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-11-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/10/11/271 |